Policy and reimbursement strategies to improve patient access to prescription digital therapeutics

1

Prescription Digital Therapeutics (PDTs) provide evidence-based treatments via FDA-cleared software but face reimbursement challenges in the U.S.
2

The Access to Prescription Digital Therapeutics Act aims to create a new benefit category for PDTs, streamlining the reimbursement process.
3

Germany's DiGA program has successfully expanded access to digital therapeutics, demonstrating the potential for similar U.S. models.
4

PDTs can bridge access gaps for underserved patients, enabling on-demand care and reducing barriers to treatment.
5

Future PDTs may leverage AI to enhance personalization and clinical outcomes, but a clear reimbursement pathway remains essential.

1